AGM/EGMJul 29, 2026, 04:12 PM
Purple Biotech AGM to Vote on Director Elections, CEO Transition & Comp Policy
AI Summary
Purple Biotech Ltd. announced its Annual General Meeting (AGM) of Shareholders to be held on September 8, 2026. Key proposals include the election of two directors, the approval of compensation terms for CEO Gil Efron as he transitions to Executive Director, Head of Corporate Development, and the adoption of a new compensation policy for executives and directors. Management will also discuss the company's 2025 financial statements.
Key Highlights
- Annual General Meeting (AGM) scheduled for Tuesday, September 8, 2026, at 4:30 p.m. Israel time.
- Shareholders to vote on the election of Mr. Gil Efron and Ms. Yael Margolin as directors until the 2029 AGM.
- Approval sought for compensation terms for Mr. Gil Efron, transitioning from CEO to Executive Director, Head of Corporate Development, effective August 31, 2026.
- Proposal to adopt an amended and restated compensation policy for executive officers and directors for a three-year period.
- Management will review and discuss the consolidated financial statements for the year ended December 31, 2025.
- Record Date for shareholders and ADS holders to vote at the Meeting is August 3, 2026.
- Intracoastal Capital LLC, Alto Opportunity Master Fund, and Lincoln Alternative Strategies LLC each beneficially own 9.99% of outstanding ordinary shares.
- Current officers and directors as a group beneficially own 1.5% (48,708,485) of outstanding ordinary shares.
Price Impact
More from PPBT